United States: Post Exclusivity Issues For Biologics

Investments in research resulting in new drug inventions have long taken advantage of patent protection, but such investments may also benefit from market exclusivities granted by the Food and Drug Administration (the "FDA"). Both patent and market exclusivities encourage and protect the significant innovation and investments required to bring a new drug to market.1

For typical small molecule pharmaceuticals, the Hatch-Waxman Act established a "regulatory framework that sought to balance incentives for continued innovation by research-based pharmaceutical companies and opportunities for market entry by generic drug manufacturers."2 Since generic versions of small molecule drugs may be chemically identical to the brand name version of the drug, a generic manufacturer can rely on FDA testing already performed on the brand name drug to support an application for approval of the generic version. This greatly increases the likelihood of entry of generic small molecule drugs into existing drug markets. Without the protections of patent rights and exclusivity incentives, pharmaceutical companies would have diminished incentives for the substantial investment to bring new small molecule drugs to market, since drug prices drop precipitously when protection expires. In the case of traditional small molecule drugs, typically manufactured through chemical synthesis, dramatic price drops of 50-60% are not unexpected.3 Hence the need for balance in marking the ambit of protection and exclusivity: too small and investment in drug innovation is discouraged; too broad, competition and consequent price reductions are too long delayed.

The challenge of striking such balances as to biologic drugs is far greater, or at least more challenging, than with respect to small molecule drugs. For unlike small molecule drugs, biologic drugs are protein-based molecules derived from living matter or manufactured through forms of biotechnology, which are of greater size and complexity than typical pharmaceuticals. Therefore, even after the patent rights and/or exclusivity rights expire for a biologic, significant technological barriers to market entry may remain after such rights expire. As a result, dramatic price decreases may not necessarily follow quickly in the wake of the expiration of patent or market exclusivities for a brand name biologic and the entry of a biologic competitor. But one must be wary of generalities: prices may in fact dramatically drop as to biologic drugs.

The Biologics Price Competition and Innovation Act of 2009 ("BPCI Act"), which became law on March 23, 2010, attempts to strike a similar balance as to biologics as Hatch-Waxman had for small molecule drugs, taking into account the technical challenges of biologics. The BPCI Act's abbreviated drug approval process is loosely modeled on that used for generic small molecule drugs, creating an abbreviated drug approval process for biologic drugs ("follow-on biologics") that are shown to be "biosimilar" or interchangeable with the brand name ("licensed") biologic drugs listed by the FDA.4 The FDA's Center for Drug Evaluation and Research provides a list of brand name biologic drugs ("reference products").

But the BPCI only sets a statutory framework. The issue is setting the balance between encouraging innovation and expanding competition. As we mentioned, the complex nature of biologic drugs raises the question of whether follow-on biologics are as safe or effective in treatment of patients as their reference products. Consequently, a follow-on biologic may require additional animal and clinical testing before gaining FDA approval, perhaps making it harder for a follow-on biologic to enter the market, even if its reference product is no longer protected by patent coverage or market exclusivity.

Occasionally though, competitors will not face the same technical challenges in entering the market with a follow-on biologic. Where a reference product is composed from molecules already well-known and established in the market, it may be much easier for competitors to produce follow-on biologics. For example, this may be true in the case of antibody-drug conjugates (ADC)or immunoconjugates, which combine small molecules and known antibodies. A pharmaceutical manufacturer of an ADC may not face the same technical hurdles as a manufacturer tackling an unknown large complex molecule. Instead, the challenges to market entry for an ADC may not be all that different from synthesizing a small molecule drug. In such instances, if generic versions of the antibody have already been manufactured and the small molecule is well-known, a follow-on biologic ADC could be produced with substantial confidence that the follow-on biologic ADC will have comparable safety, efficacy and ease of use to that of the reference product, sufficient to warrant FDA approval. In such an instance, the price of a post-patent rights, post-market exclusivity biologic may be expected to behave more like a small molecule drug facing generic competition than other biologics.

The BPCI Act itself provides that its 12 year market exclusivity for reference product biologics does not apply to minor changes to a biologic, such as a "new indication, route of administration, dosing schedule, dosage form, delivery system, delivery device, or strength" or "a modification to the structure of the biological product that does not result in a change in safety, purity or potency." 42 U.S.C. § 262(k)(7)(c). Indeed, extending exclusivity for brand name biologics comprised of previously well-known components, which may have already enjoyed their own market exclusivities, may raise anti-trust concerns not unlike those raised by the FTC in its Brief as Amicus Curiae, Mylan Pharm., Inc. v. Warner Chilcott Pub. Co., No. 12-3824 (E.D. Pa. Dec. 3, 2012), ECF No. 122. In that amicus brief, the FTC asserted that "pharmaceutical product redesigns can constitute exclusionary conduct" where the brand company withdraws the original product from the market or "achieve[s] the same result through indirect means . . . ." Id. at 10, 13. The brief went on to assert that the plaintiffs had asserted a plausible claim that "the defendants' product reformulations constitute an unlawful means of preserving monopoly power in violation of Section 2 of the Sherman Act." Id. at 14. Attempting to maintain market exclusivity through impermissible conduct that has the effect of effectively lengthening the term of patent rights or improperly broadening the scope of a patent could implicate the policy concerns underlying patent misuse doctrine. See Hovenkamp, Janis, Lemley and Leslie, IP and Antitrust, Chp 3 (2nd ed. Update 2014) (general description of patent misuse doctrine). See also, Princo Corp. v. International Trade Commission, 96 USPQ2d 1233, 1239 (Fed. Cir. 2010) ("The doctrine of patent misuse is thus grounded in the policy-based desire to 'prevent a patentee from using the patent to obtain market benefit beyond that which inheres in the statutory patent right."'). Cf. Brulotte v. Thys Co., 379 U.S. 29, 32 (1964) ("a patentee's use of a royalty agreement that projects beyond the expiration date of the patent is unlawful per se"; the continuing vitality of Brulotte will be the subject of Supreme Court review this term. See, Kimble v. Marvel Enterprises, Inc., 727 F.3d 856, (9th. Cir. 2013), petition for cert. granted, 82 USLW 3379, No. 13-720, (Dec. 12, 2014) (the Supreme Court will consider whether a royalty agreement that projects beyond the expiration date of the patent is unlawful per se)). In addition, minor changes and reformulations to well-known products can, of course, also be attacked under the patent laws on grounds of lack of novelty or anticipation and obviousness.

Ultimately, whether any given brand name biologic drug is vulnerable to market entry by a follow-on biologic may depend on the degree of its reliance on well-understood components. As described for ADC's above, some brand name biologics may therefore be vulnerable to the typical 50-60% price drop seen in cases of generic small molecule competition. Accordingly, a careful review of the composition of a biologic drug is another factor that merits consideration in evaluating the advantages that may be provided by exclusivities.


1. While calculating the costs to bring a drug to market will vary widely based upon a multitude of factors, at least one recent study released by the Tufts Center for the Study of Drug Development, has projected the current out of pocket costs from development through market approval of the drug at approximately $1.4 billion. "Cost to Develop and Win Marketing Approval for a New Drug Is $2.6 Billion", November 18, 2014, Tufts Center for the Study of Drug Development. http://csdd.tufts.edu/news/complete_story/pr_tufts_csdd_2014_cost_study.

2. Prepared Statement of the Federal Trade Commission Before the Committee on Judiciary, United States Senate (June 17, 2003).

3. Frank R. Lichtenberg and Gautier Duflos, "Time Release: The Effect of Patent Expiration on U.S. Drug Prices, Marketing, and Utilization by the Public," Medical Progress Report, No. 11, October 2009.

4. A follow-on biologic is biosimilar to a brand-name product if it is deemed to be "highly similar to the reference product notwithstanding minor differences in clinically inactive components" and "there are no clinically meaningful differences between the [biosimilar] and the reference product in terms of safety, purity, and potency of the product." 42 U.S.C. § 262(i)(2). A follow-on biologic is interchangeable if it meets the standard for biosimilarity and (1) it can be expected to produce the same clinical result as the reference product in any given patient and (2) for a product administered more than once, the risk, in terms of safety or diminished efficacy of switching between the two products, is not greater than the use of the reference product without such alternation. 42 U.S.C. § 262(k)(4).

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:
  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.
  • Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.
    If you do not want us to provide your name and email address you may opt out by clicking here
    If you do not wish to receive any future announcements of products and services offered by Mondaq you may opt out by clicking here

    Terms & Conditions and Privacy Statement

    Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

    Use of www.mondaq.com

    You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


    Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

    The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


    Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

    • To allow you to personalize the Mondaq websites you are visiting.
    • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
    • To produce demographic feedback for our information providers who provide information free for your use.

    Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

    Information Collection and Use

    We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

    We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

    Mondaq News Alerts

    In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


    A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

    Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

    Log Files

    We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


    This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

    Surveys & Contests

    From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


    If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


    From time to time Mondaq may send you emails promoting Mondaq services including new services. You may opt out of receiving such emails by clicking below.

    *** If you do not wish to receive any future announcements of services offered by Mondaq you may opt out by clicking here .


    This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

    Correcting/Updating Personal Information

    If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

    Notification of Changes

    If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

    How to contact Mondaq

    You can contact us with comments or queries at enquiries@mondaq.com.

    If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.

    By clicking Register you state you have read and agree to our Terms and Conditions